Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infectious Diseases

Set Alert for Infectious Diseases

Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction

Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.

China Vaccines

Global Health Leaders Highlight Pandemic Preparedness

At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.

South Korea Infectious Diseases

Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?

Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound.

Commercial Companies

All About Scale: GSK Eyes China Partnerships To Ramp Up Vaccine Access

GSK is betting on a new partnership to more quickly ramp up patient access to its vaccines in the potentially vast market of China, amid rising demand and competition.

China Commercial

Innoviva Aims For A First-In-Class Antibiotic

Zoliflodacin could become the first new antibiotic for treating gonorrhea in decades, but can it change guidelines?

Clinical Trials Companies

A Stellar Launch For RSV Vaccine Arexvy Lifts GSK

GSK has enjoyed a better-than-expected launch for its RSV vaccine, but emphasized that it was still early days, and the firm is not altering its £3bn peak annual sales forecast for the product.

Sales & Earnings Companies

GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development

Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.

Deals Business Strategies

In Competitive RSV Market, GSK Aims To Be First For Adults 50-59

Results from a Phase III trial testing the RSV vaccine Arexvy in adults 50-59 met the two primary endpoints, potentially opening the door to a wider adult market.

Vaccines Infectious Diseases

It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever

But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.

Deals Cancer

Gilead Adds To Virology Focus Through 12-Year Collaboration With Assembly

Gilead gets option rights to Assembly’s entire virology pipeline, including future assets, for herpesvirus and hepatitis B and D. The deal provides financial stability and opt-in potential for Assembly.

Deals Business Strategies

Moderna Marches Into Phase III With COVID/Flu Vaccine Combo

The US biotech major says that preliminary data show that its mRNA-1083 combination vaccine yielded antibody levels in the blood similar to or greater than two Sanofi flu vaccines and its own COVID-19 shot Spikevax.

Coronavirus COVID-19 Vaccines

ViiV In It For The Long Haul In HIV Market Battle With Gilead

The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.

Infectious Diseases Business Strategies
See All